Back to Search
Start Over
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
- Publication Year :
- 2017
-
Abstract
- The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse
- Subjects :
- Oncology
medicine.medical_specialty
Neoplasm, Residual
medicine.medical_treatment
Salvage therapy
Hematopoietic stem cell transplantation
Transplantation, Autologous
Article
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Chemoimmunotherapy
Recurrence
Risk Factors
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Treatment Failure
Aged
Retrospective Studies
Salvage Therapy
business.industry
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
medicine.disease
Lymphoma
Surgery
Transplantation
Clinical trial
Benchmarking
030220 oncology & carcinogenesis
Multivariate Analysis
Disease Progression
Rituximab
Lymphoma, Large B-Cell, Diffuse
business
Diffuse large B-cell lymphoma
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....e8bc0b35f391771266ae0fa56cdcce5d